These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 28245859)

  • 81. A Comparative Study of Clinical Outcomes in Locally Advanced Cervical Cancer: External Beam Radiotherapy (EBRT) and Sequential High Dose Rate Intracavitary Brachytherapy (HDRICBT) with or without Concurrent Cisplatin on the Day of ICBT Insertion - A Tertiary Care Center Randomized Controlled Trial in India.
    Alim S; Siddiqui SA; Akram M; Hakim S; Khan MA
    Asian Pac J Cancer Prev; 2024 Apr; 25(4):1333-1338. PubMed ID: 38679994
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Combined chemoradiation of cisplatin versus carboplatin in cervical carcinoma: a single institution experience from Thailand.
    Tharavichitkul E; Lorvidhaya V; Kamnerdsupaphon P; Sukthomya V; Chakrabandhu S; Klunklin P; Onchan W; Supawongwattana B; Pukanhaphan N; Galalae R; Chitapanarux I
    BMC Cancer; 2016 Jul; 16():501. PubMed ID: 27435245
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Feasibility study of Californium-252 for the therapy of stage IV cervical cancer.
    Maruyama Y; Van Nagell JR; Yoneda J; Donaldson E; Gallion H; Patel P; Kryscio RJ
    Cancer; 1988 Jun; 61(12):2448-52. PubMed ID: 3130179
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Clinical assessment of 252Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for endometrial cancer.
    Zhou Q; Tang C; Zhao KW; Xiong YL; Chen S; Xu WJ; Lei X
    Clinics (Sao Paulo); 2016 Jan; 71(1):10-6. PubMed ID: 26872078
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Pre-treatment MRI minimum apparent diffusion coefficient value is a potential prognostic imaging biomarker in cervical cancer patients treated with definitive chemoradiation.
    Marconi DG; Fregnani JH; Rossini RR; Netto AK; Lucchesi FR; Tsunoda AT; Kamrava M
    BMC Cancer; 2016 Jul; 16():556. PubMed ID: 27469349
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Treatment Outcome and Prognosis Factors of FIGO 2018 Stage III Cervical Cancer Patients Treated with Definitive Concurrent Chemoradiation in Vietnam.
    Phung HT; Truong MC; Nguyen LT; Dang ATV; Vu TH; Nguyen HT
    Asian Pac J Cancer Prev; 2021 Mar; 22(3):853-859. PubMed ID: 33773550
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Therapeutic dosimetry for Cf-252 neutron brachytherapy of pelvic cancer.
    Maruyama Y; Beach JL; Hazle J; Ashtari M; Schroy CB; Olson MH
    Int J Radiat Oncol Biol Phys; 1985 May; 11(5):927-35. PubMed ID: 3921501
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Definitive Chemoradiotherapy in Elderly Cervical Cancer Patients: A Multiinstitutional Analysis.
    Guler OC; Sari SY; Birgi SD; Gultekin M; Yildiz F; Onal C
    Int J Gynecol Cancer; 2017 Sep; 27(7):1446-1454. PubMed ID: 28604459
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Concurrent chemoradiotherapy or radiotherapy alone for locally advanced cervical cancer in elderly women.
    Park JH; Kim YS; Ahn SD; Choi EK; Shin SS; Kim YT; Kim YM; Kim JH; Yi SY; Nam JH
    Tumori; 2010; 96(6):959-65. PubMed ID: 21388059
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Evaluating contemporary radiotherapy approaches in the primary treatment of cervical cancer.
    Samant R; Kobeleva S; E C; Balaraj K; Le T; Fung-Kee-Fung M
    Int J Gynecol Cancer; 2010 Aug; 20(6):1087-91. PubMed ID: 20683423
    [TBL] [Abstract][Full Text] [Related]  

  • 91. A retrospective study of californium-252 neutron brachytherapy combined with EBRT versus 3D-CRT in the treatment of esophageal squamous cell cancer.
    Wang Q; Li T; Lang J; Wang J; Wang J; Liu H; Jia X; Liu B; Wang CK
    Radiat Oncol; 2015 Oct; 10():212. PubMed ID: 26499111
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Clinical trial of 252Cf neutron brachytherapy vs. conventional radiotherapy for advanced cervical cancer.
    Maruyama Y; Kryscio R; Van Nagell JR; Yoneda J; Donaldson E; Hanson M; Beach JL; Feola JM; Martin A; Parker C
    Int J Radiat Oncol Biol Phys; 1985 Aug; 11(8):1475-82. PubMed ID: 4019271
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Five-year cure of cervical cancer treated using californium-252 neutron brachytherapy.
    Maruyama Y; van Nagell JR; Yoneda J; Donaldson E; Hanson M; Martin A; Wilson LC; Coffey CW; Feola J; Beach JL
    Am J Clin Oncol; 1984 Oct; 7(5):487-93. PubMed ID: 6391143
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy.
    Rose PG; Java J; Whitney CW; Stehman FB; Lanciano R; Thomas GM; DiSilvestro PA
    J Clin Oncol; 2015 Jul; 33(19):2136-42. PubMed ID: 25732170
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Comparison of chemoradiotherapy with and without brachytherapy as adjuvant therapy after radical surgery in early-stage cervical cancer with poor prognostic factors: An observational study.
    Lan ML; Yu X; Xiao H; Zhou P; Hu N; Liu Y; Wang G
    Medicine (Baltimore); 2017 Nov; 96(46):e8384. PubMed ID: 29145247
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A clinical trial for advanced cervico-vaginal pelvic carcinomas using Californium Cf-252 fast neutron therapy: report of early responses.
    Maruyama Y; Yoneda J; Krolikiewicz H; Mendiondo O; Beach JL; Coffey CW; Thompson D; Wilson LC; Feola J; Van Nagell JR; Donaldson ES; Powell D
    Int J Radiat Oncol Biol Phys; 1980 Dec; 6(12):1629-37. PubMed ID: 6263831
    [No Abstract]   [Full Text] [Related]  

  • 97. The influence of cisplatin dose upon survival in concurrent chemoradiotherapy of locally advanced cervical carcinoma with weekly cisplatin.
    Sirák I; Petera J; Zoul Z
    Acta Medica (Hradec Kralove); 2008; 51(2):95-9. PubMed ID: 18998360
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Weekly versus triweekly cisplatin-alone adjuvant chemoradiotherapy after radical hysterectomy for stages IB-IIA cervical cancer with risk of recurrence.
    Zhu J; Lou R; Ji S; Wu G; Chen Q; Hu Q; Zhao Y; Cai D; Gu K
    Anticancer Drugs; 2021 Feb; 32(2):203-209. PubMed ID: 33186140
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Intermediate-term results of trans-abdominal ultrasound (TAUS)-guided brachytherapy in cervical cancer.
    Tharavichitkul E; Chakrabandhu S; Klunklin P; Onchan W; Jia-Mahasap B; Wanwilairat S; Tippanya D; Jayasvasti R; Sripan P; Galalae RM; Chitapanarux I
    Gynecol Oncol; 2018 Mar; 148(3):468-473. PubMed ID: 29398070
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Outcomes in 24 selected patients with stage IVB cervical cancer and excellent performance status treated with radiotherapy and chemotherapy.
    Zighelboim I; Taylor NP; Powell MA; Gibb RK; Rader JS; Mutch DG; Grigsby PW
    Radiat Med; 2006 Nov; 24(9):625-30. PubMed ID: 17111271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.